140 related articles for article (PubMed ID: 30240563)
1. Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
Provencher BA; Eshleman AJ; Johnson RA; Shi X; Kryatova O; Nelson J; Tian J; Gonzalez M; Meltzer PC; Janowsky A
J Med Chem; 2018 Oct; 61(20):9121-9131. PubMed ID: 30240563
[TBL] [Abstract][Full Text] [Related]
2. Identification of the substrate binding region of vesicular monoamine transporter-2 (VMAT-2) using iodoaminoflisopolol as a novel photoprobe.
Gopalakrishnan A; Sievert M; Ruoho AE
Mol Pharmacol; 2007 Dec; 72(6):1567-75. PubMed ID: 17766642
[TBL] [Abstract][Full Text] [Related]
3. GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.
Horton DB; Nickell JR; Zheng G; Crooks PA; Dwoskin LP
J Neurochem; 2013 Oct; 127(2):177-86. PubMed ID: 23875622
[TBL] [Abstract][Full Text] [Related]
4. Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.
Nickell JR; Zheng G; Deaciuc AG; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2011 Mar; 336(3):724-33. PubMed ID: 20876747
[TBL] [Abstract][Full Text] [Related]
5. The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.
Nickell JR; Siripurapu KB; Vartak A; Crooks PA; Dwoskin LP
Adv Pharmacol; 2014; 69():71-106. PubMed ID: 24484975
[TBL] [Abstract][Full Text] [Related]
6. Lobelane analogues containing 4-hydroxy and 4-(2-fluoroethoxy) aromatic substituents: Potent and selective inhibitors of [(3)H]dopamine uptake at the vesicular monoamine transporter-2.
Joolakanti SR; Nickell JR; Janganati V; Zheng G; Dwoskin LP; Crooks PA
Bioorg Med Chem Lett; 2016 May; 26(10):2422-2427. PubMed ID: 27080180
[TBL] [Abstract][Full Text] [Related]
7. GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine.
Lee NR; Zheng G; Leggas M; Janganati V; Nickell JR; Crooks PA; Bardo MT; Dwoskin LP
J Pharmacol Exp Ther; 2019 Nov; 371(2):526-543. PubMed ID: 31413138
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors.
Yang Y; Yu D; Zhu X; Du G; Wang W; Zou F; Wang H; Zhang R; Ye L; Tian J
Eur J Med Chem; 2021 Nov; 224():113718. PubMed ID: 34329999
[TBL] [Abstract][Full Text] [Related]
9. New fluorescent substrate enables quantitative and high-throughput examination of vesicular monoamine transporter 2 (VMAT2).
Hu G; Henke A; Karpowicz RJ; Sonders MS; Farrimond F; Edwards R; Sulzer D; Sames D
ACS Chem Biol; 2013 Sep; 8(9):1947-54. PubMed ID: 23859623
[TBL] [Abstract][Full Text] [Related]
10. A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.
Bernstein AI; Stout KA; Miller GW
J Neurosci Methods; 2012 Aug; 209(2):357-66. PubMed ID: 22698664
[TBL] [Abstract][Full Text] [Related]
11. Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [
Hankosky ER; Joolakanti SR; Nickell JR; Janganati V; Dwoskin LP; Crooks PA
Bioorg Med Chem Lett; 2017 Dec; 27(24):5467-5472. PubMed ID: 29153425
[TBL] [Abstract][Full Text] [Related]
12. 1,4-Diphenalkylpiperidines: A new scaffold for the design of potent inhibitors of the vesicular monoamine transporter-2.
Nickell JR; Culver JP; Janganati V; Zheng G; Dwoskin LP; Crooks PA
Bioorg Med Chem Lett; 2016 Jul; 26(13):2997-3000. PubMed ID: 27212067
[TBL] [Abstract][Full Text] [Related]
13. Pyrrolidine analogs of GZ-793A: synthesis and evaluation as inhibitors of the vesicular monoamine transporter-2 (VMAT2).
Penthala NR; Ponugoti PR; Nickell JR; Deaciuc AG; Dwoskin LP; Crooks PA
Bioorg Med Chem Lett; 2013 Jun; 23(11):3342-5. PubMed ID: 23597792
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2.
Yasumoto S; Tamura K; Karasawa J; Hasegawa R; Ikeda K; Yamamoto T; Yamamoto H
Neurosci Lett; 2009 May; 454(3):229-32. PubMed ID: 19429089
[TBL] [Abstract][Full Text] [Related]
15. meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
Horton DB; Siripurapu KB; Norrholm SD; Culver JP; Hojahmat M; Beckmann JS; Harrod SB; Deaciuc AG; Bardo MT; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2011 Mar; 336(3):940-51. PubMed ID: 21177475
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and in vitro evaluation of water-soluble 1,4-diphenethylpiperazine analogs as novel inhibitors of the vesicular monoamine transporter-2.
Nickell JR; Culver JP; Janganati V; Zheng G; Dwoskin LP; Crooks PA
Bioorg Med Chem Lett; 2016 Sep; 26(18):4441-4445. PubMed ID: 27524311
[TBL] [Abstract][Full Text] [Related]
17. New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders.
Lee NR; Zheng G; Crooks PA; Bardo MT; Dwoskin LP
AAPS J; 2018 Feb; 20(2):29. PubMed ID: 29427069
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2.
Pidathala S; Liao S; Dai Y; Li X; Long C; Chang CL; Zhang Z; Lee CH
Nature; 2023 Nov; 623(7989):1086-1092. PubMed ID: 37914936
[TBL] [Abstract][Full Text] [Related]
19. The psychostimulant (±)-cis-4,4'-dimethylaminorex (4,4'-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters.
Maier J; Mayer FP; Luethi D; Holy M; Jäntsch K; Reither H; Hirtler L; Hoener MC; Liechti ME; Pifl C; Brandt SD; Sitte HH
Neuropharmacology; 2018 Aug; 138():282-291. PubMed ID: 29908239
[TBL] [Abstract][Full Text] [Related]
20. Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter.
Zheng G; Dwoskin LP; Deaciuc AG; Norrholm SD; Crooks PA
J Med Chem; 2005 Aug; 48(17):5551-60. PubMed ID: 16107155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
